RxDoctor Payments Data

Hardeep Dhindsa, MD

Ophthalmology · Reno, NVNPI 1366402570

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations.

$3,005in general payments, 2019–2025

Across 65 payments — averaging $46.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$570
  • Apellis Pharmaceuticals, Inc.$534
  • Genentech USA, Inc.$471
  • Novartis$425
  • Dutch Ophthalmic, USA$230
  • Genentech, Inc.$218
  • plus $557 from 11 others

What the payments were for

  • Food & beverage$3,005100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,005 in reported general payments places this provider in the 65th percentile of 121 ophthalmology providers in Nevada.

See all ophthalmology providers in Nevada

Medicare billing

Part B allowed, 2024
$2,774,869
Medicare patients
1,659
Services billed
50,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate242$12,489
Difluprednate23$2,557
Ketorolac Tromethamine34$977
Latanoprost70$768
Tobramycin115$611
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat25$437
Dorzolamide Hcl16$397
Timolol Maleate44$273
MoxifloxacinMoxifloxacin Hcl11$165

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →